KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.

Mototsugu Oya, Jae Young Joung, Ji Youl Lee, Mikio Sugimoto, Young Deuk Choi, Jun Hyuk Hong, Hiroji Uemura, Kazuo Nishimura, Hideyasu Tsumura, Satoru Kawakami, Yukiyoshi Hirayama, Tae Gyun Kwon, Cheol Kwak, Hiroyoshi Suzuki, Tomoko Fujita, Masahiro Nii, David McGuinness, Melanie Dujka, Christian Poehlein, Fred Saad, Noel Clarke

Cancer Sci 116(6) 1638-1647

PMID40099663
PMCIDPMC12127112
DOI10.1111/cas.16459
发表日期2025-03-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the phase 3 PROpel trial (NCT03732820) patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib plus abiraterone in the first-line setting showed significantly prolonged radiographic progression-free survival (rPFS; primary data cutoff [DCO]: 30 July 2021; hazard ratio [HR] 0.66, 95% confidence interval [CI], 0.54-0.81; p < 0.001), and at prespecified final OS analysis DCO (12 October 2022) numerically prolonged overall survival (OS; HR 0.81, 95% CI, 0.67-1.00; p = 0.054), versus placebo plus abiraterone for the global population. Here, we report efficacy, safety, and patient-reported outcome data for the Asian subset in PROpel. Eligible patients were randomly assigned (1:1) to either olaparib (300 mg twice daily) or placebo in combination with abiraterone (1000 mg once daily). The primary endpoint was investigator-assessed rPFS, and a key secondary endpoint was OS. In the Asian subset (n = 133) at primary analysis, median rPFS was 27.6 months in the olaparib plus abiraterone arm (n = 63), compared with 19.3 months in the placebo plus abiraterone arm (n = 70; HR 0.55, 95% CI, 0.32-0.95). Median OS at the final analysis was not reached in the olaparib plus abiraterone arm versus 43.7 months in the placebo plus abiraterone arm (HR 0.59, 95% CI, 0.32-1.06). The safety profile was generally similar in the Asian subset and the global population. Efficacy and safety results for olaparib plus abiraterone in the Asian subset were generally consistent with the global PROpel population supporting the combination of olaparib plus abiraterone as an important first-line treatment for consideration in Asian patients with mCRPC. Trial Registration: Clinicaltrials.gov identifier: NCT03732820.

KM 提取结果

3 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 1

FIGURE 1 Kaplan–Meier estimate curves for rPFS by investigator assessment in the Asian subset (DCO: 30 July 2021). A circle indicates a censored observation. HR and CIs were calculated using a Cox proportional hazards model adjusted for the variables selected in the primary pooling strategy: metastases and docetaxel treatment at mHSPC stage. CI, confidence interval; DCO, data cutoff; HR, hazard ratio; mHSPC, metastatic hormone‐sensitive prostate cancer; NC, not calculable; rPFS, radiographic progression‐free survival.

rPFS_Asian_subset

rPFS

FIGURE 1 · Panel rPFS_Asian_subset

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel rPFS_Asian_subset 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

FIGURE 2

FIGURE 2 Kaplan–Meier estimate curves for OS in the Asian subset (DCO: 12 October 2022). A circle indicates a censored observation. HR and CIs were calculated using a Cox proportional hazards model adjusted for the variables selected in the primary pooling strategy: metastases and docetaxel treatment at mHSPC stage. CI, confidence interval; DCO, data cutoff; HR, hazard ratio; NC, not calculable; mHSPC, metastatic hormone‐sensitive prostate cancer; OS, overall survival.

Kaplan_Meier_estimate_curves_for_OS

OS

FIGURE 2 · Panel Kaplan_Meier_estimate_curves_for_OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan_Meier_estimate_curves_for_OS 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIGURE 3

FIGURE 3 Kaplan–Meier estimate curves for TFST in the Asian subset (DCO: 12 October 2022). A circle indicates a censored observation. HR and CIs were calculated using a Cox proportional hazards model adjusted for the variables selected in the primary pooling strategy: metastases and docetaxel treatment at mHSPC stage. CI, confidence interval; DCO, data cutoff; HR, hazard ratio; mHSPC, metastatic hormone‐sensitive prostate cancer; NC, not calculable; TFST, time to first subsequent therapy.

TFST

time to first subsequent therapy

FIGURE 3 · Panel TFST

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel TFST 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果